Dynamic-interaction of vitamin K and levamisole on phenylbutazone activities.
The results showed that co-administration of either vitamin K or levamisole along with phenylbutazone abolished the latter's anti-inflammatory and antipyretic activities and reduced its analgesic effect. Prolonged administration of phenylbutazone alone to rats for 21 days increased significantly serum glutamate oxalacetate transaminase (SGOT) activity, urea and creatinine concentrations, while it decreased with significance uric acid concentration in the serum. Vitamin K, when administered together with phenylbutazone, reduced its effect on SGOT activity and creatinine concentration. Levamisole antagonised the uricosuric effect of phenylbutazone, when both were concomitantly given. Histopathological examination of the liver of rats, given phenylbutazone alone, showed mild degenerative changes, whereas in combination with levamisole these changes were exacerbated. Kidney showed oedema, degeneration, congestion, and haemorrhage. These changes were severe in rats, given phenylbutazone alone, moderate in levamisole-treated animals, and mild in those given both drugs. Combination of levamisole with phenylbutazone not only decreased the congestion of gastric mucosa but also activated the gastric glands.
Shalaby
M A
MA
Faculty of Veterinary Medicine, Pharmacology and Pathology Department, Cairo University (Giza and Beni-Suef), Egypt.
Ibrahim
M
M
el Bauomy
A M
AM
el Begawy
M
M
D000698:Analgesia; D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D004347:Drug Interactions; D005260:Female; D007249:Inflammation / Q000188:drug therapy; D007978:Levamisole / Q000494:pharmacology*; D008297:Male; D010653:Phenylbutazone / Q000494:pharmacology*; D051381:Rats; D014812:Vitamin K / Q000494:pharmacology*
D014812:Vitamin K; D007978:Levamisole; D010653:Phenylbutazone